Exploring Cancer Evolution, Prognostic and Predictive Biomarkers in EGFR-mutant NSCLC
Recruiting · NCT05997719 · Observational (researchers observe without assigning treatment)
View the official record on ClinicalTrials.gov →What this trial is about
To investigate genomic architecture, cancer evolution and their relationship with clinical outcomes in EGFR-mutant NSCLC.
Who can take part
Age range
18 Years and older
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Not specified
Study type
Observational (researchers observe without assigning treatment)
Inclusion criteria
- Aged 18 years or older
- Histologically or cytologically confirmed non-small-cell lung cancer
- ECOG PS=0-2
- EGFR mutations confirmed by tissue or peripheral blood
- Can provide tumor tissue samples (fresh or archived)
- The subject should have good compliance, who would participate in the research voluntarily, and sign the informed consent
Exclusion criteria
- History of other malignancies within 5 years (excluding basal cell carcinoma of the skin or other carcinoma in situ that has been resected).
- Unable to provide sufficient tumor tissue for analysis.
- Subjects with active, unstable systemic diseases, such as active infection, uncontrolled hypertension, heart failure (NYHA class \>= II), unstable angina pectoris, acute coronary syndrome, severe arrythmia, severe liver, kidney or metabolic diseases, HIV infection.
- Subjects who are deemed unable to comply with the study requirements or complete the study.
Where it is running
1 location listed.
- Sun Yat-sen University Cancer Center - Guanzhou, China